Causes of death in locally advanced esophageal cancer undergoing neoadjuvant chemotherapy and neoadjuvant chemoradiotherapy: a retrospective cohort study
Diseases of the Esophagus · 2025
DOI: 10.1093/dote/doaf017 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Diseases of the Esophagus, 2025. Verfasst von Dong Liu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Therapy, Zhejiang Cancer Hospital, Hangzhou, Zhejiang 310022, P.R. China. Hauptthemen laut MEDLINE: Esophageal Neoplasms, Neoadjuvant Therapy, Chemoradiotherapy, Adjuvant. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 27 Literaturangaben.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Purpose
To compare the causes of death in patients with locally advanced esophageal cancer treated with neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy followed by surgery. Materials and methods A retrospective cohort study was conducted on patients with stage T3-4aN0M0/T1-4aN1-3 M0 esophageal cancer who underwent either neoadjuvant chemotherapy or neoadjuvant chemoradiotherapy followed by surgery. Overall survival (OS) and specific causes of death were analyzed and compared between the two treatment groups.
Results
A total of 4528 patients were included: 333 (7.4%) received neoadjuvant chemotherapy, and 4195 (92.6%) underwent neoadjuvant chemoradiotherapy. The 5-year OS was comparable between the two groups, both before (42.4% vs. 39.7%; hazard ratio [HR] = 1.14, 95% confidence interval [CI]: 0.98-1.33; P = 0.097) and after (42.2% vs. 42.2%; HR = 1.07, 95% CI: 0.86-1.31; P = 0.567) propensity score matching. The cumulative 5-year absolute risk of death from esophageal cancer (49.9% vs. 50.6%, P = 0.470), death from non-tumor causes (7.8% vs. 9.7%, P = 0.160), death due to lung causes (2.8% vs. 1.4%, P = 0.432), and death from heart-related causes (2.2% vs. 2.0%, P = 0.524) were similar between the two treatment groups.
Conclusion
In patients with locally advanced esophageal cancer, OS and the causes of death were comparable between those receiving neoadjuvant chemotherapy and those undergoing neoadjuvant chemoradiotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Radiation Therapy, Zhejiang Cancer Hospital, Hangzhou, Zhejiang 310022, P.R. China.
- Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, No. 150 Dongfang Road, Qiantang District, Hangzhou, Zhejiang 310018, P.R. China.
- Department of Radiation Oncology, Guangxi Medical University Cancer Hospital, No. 71 Hedi Road, Qingxiu District, Nanning, Guangxi 530021, P.R. China.
ORCID-Profile: Xin-Bin Pan
Zitieren
APA
Liu, D., Liang, H. W., Liu, Y., Huang, W., & Pan, X. B. (2025). Causes of death in locally advanced esophageal cancer undergoing neoadjuvant chemotherapy and neoadjuvant chemoradiotherapy: a retrospective cohort study. Diseases of the Esophagus. https://doi.org/10.1093/dote/doaf017
Vancouver
Liu D, Liang HW, Liu Y, Huang W, Pan XB. Causes of death in locally advanced esophageal cancer undergoing neoadjuvant chemotherapy and neoadjuvant chemoradiotherapy: a retrospective cohort study. Diseases of the Esophagus. 2025. doi:10.1093/dote/doaf017
BibTeX
@article{Liu2025,
author = {Liu, Dong and Liang, Huan-Wei and Liu, Yang and Huang, Wei and Pan, Xin-Bin},
title = {Causes of death in locally advanced esophageal cancer undergoing neoadjuvant chemotherapy and neoadjuvant chemoradiotherapy: a retrospective cohort study},
journal = {Diseases of the Esophagus},
year = {2025},
doi = {10.1093/dote/doaf017}
}
EUVIMED